Cargando…

Discovering Distinct Phenotypical Clusters in Heart Failure Across the Ejection Fraction Spectrum: a Systematic Review

REVIEW PURPOSE: This systematic review aims to summarise clustering studies in heart failure (HF) and guide future clinical trial design and implementation in routine clinical practice. FINDINGS: 34 studies were identified (n = 19 in HF with preserved ejection fraction (HFpEF)). There was significan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meijs, Claartje, Handoko, M. Louis, Savarese, Gianluigi, Vernooij, Robin W. M., Vaartjes, Ilonca, Banerjee, Amitava, Koudstaal, Stefan, Brugts, Jasper J., Asselbergs, Folkert W., Uijl, Alicia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589200/ https://www.ncbi.nlm.nih.gov/pubmed/37477803 http://dx.doi.org/10.1007/s11897-023-00615-z

Ejemplares similares

A registry‐based algorithm to predict ejection fraction in patients with heart failure
por: Uijl, Alicia, et al.
Publicado: (2020)

Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction
por: Uijl, Alicia, et al.
Publicado: (2021)

Generalizability of randomized controlled trials in heart failure with reduced ejection fraction
por: Lim, Yvonne Mei Fong, et al.
Publicado: (2021)

Temporal trends in heart failure medication prescription in a population-based cohort study
por: Uijl, Alicia, et al.
Publicado: (2021)

Multimorbidity in Heart Failure: Leveraging Cluster Analysis to Guide Tailored Treatment Strategies
por: van de Veerdonk, Mariëlle C., et al.
Publicado: (2023)

Risk factors for incident heart failure in age‐ and sex‐specific strata: a population‐based cohort using linked electronic health records
por: Uijl, Alicia, et al.
Publicado: (2019)

Clinical profile and contemporary management of patients with heart failure with preserved ejection fraction: results from the CHECK-HF registry
por: Uijl, A., et al.
Publicado: (2021)

Trends for Readmission and Mortality After Heart Failure Hospitalisation in Malaysia, 2007 to 2016
por: Lim, Yvonne Mei Fong, et al.
Publicado: (2022)

Heart failure with preserved, mid‐range, and reduced ejection fraction across health care settings: an observational study
por: de Boer, Annemarijn R., et al.
Publicado: (2021)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction
por: Stolfo, Davide, et al.
Publicado: (2022)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2022)

Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
por: Stolfo, Davide, et al.
Publicado: (2019)

Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction
por: Kapelios, Chris J, et al.
Publicado: (2023)

Algorithms used in telemonitoring programmes for patients with chronic heart failure: A systematic review
por: Brons, Maaike, et al.
Publicado: (2018)

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
por: Stolfo, Davide, et al.
Publicado: (2023)

Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction
por: Löfström, Ulrika, et al.
Publicado: (2019)

Persistent High Burden of Heart Failure Across the Ejection Fraction Spectrum in a Nationwide Setting
por: Stolfo, Davide, et al.
Publicado: (2022)

Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction
por: Veenis, Jesse F, et al.
Publicado: (2019)

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata
por: Stolfo, Davide, et al.
Publicado: (2022)

Left ventricular remodelling and prognosis after discharge in new‐onset acute heart failure with reduced ejection fraction
por: van den Berge, Jan C., et al.
Publicado: (2021)

Network meta‐analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction
por: De Marzo, Vincenzo, et al.
Publicado: (2022)

Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry
por: Kapelios, Chris J, et al.
Publicado: (2021)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
por: Lund, Lars H., et al.
Publicado: (2021)

How to diagnose heart failure with preserved ejection fraction: the value of invasive stress testing
por: Huis in ’t Veld, A. E., et al.
Publicado: (2016)

Long‐term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non‐cardiac mortality
por: Shahim, Angiza, et al.
Publicado: (2023)

Real-world management of heart failure in the Netherlands: Improving quality of care by simple measures
por: Koudstaal, S., et al.
Publicado: (2018)

Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry
por: D'Amario, Domenico, et al.
Publicado: (2022)

Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry
por: Lindberg, Felix, et al.
Publicado: (2022)

Predictors of long‐term outcome in heart failure with preserved ejection fraction: a follow‐up from the KaRen study
por: Shahim, Angiza, et al.
Publicado: (2021)

Deep phenotyping meets big data: the Geoscience and hEalth Cohort COnsortium (GECCO) data to enable exposome studies in The Netherlands
por: Lakerveld, Jeroen, et al.
Publicado: (2020)

Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Correction to: Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Diagnostic value of echocardiographic markers for diastolic dysfunction and heart failure with preserved ejection fraction
por: Dal Canto, Elisa, et al.
Publicado: (2020)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Cardiac resynchronization therapy with or without defibrillator in patients with heart failure
por: Schrage, Benedikt, et al.
Publicado: (2021)

Predictors of primary prevention implantable cardioverter‐defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all‐cause mortality
por: Schrage, Benedikt, et al.
Publicado: (2022)

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction
por: Teramoto, Kanako, et al.
Publicado: (2022)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_78a80mji1di4au5s8tb829hjsl